Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Wunsch, S; Krause, R; Valentin, T; Prattes, J; Janata, O; Lenger, A; Bellmann-Weiler, R; Weiss, G; Zollner-Schwetz, I.
Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
Int J Infect Dis. 2019; 81:210-214
Doi: 10.1016/j.ijid.2019.02.013
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Wunsch Stefanie
- Zollner-Schwetz Ines
- Co-authors Med Uni Graz
- Krause Robert
- Prattes Jürgen
- Valentin Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Dalbavancin, a lipoglycopeptide with prolonged half-life approved for the treatment of acute bacterial skin and soft tissue infections, can be used for the treatment of infections caused by gram-positive bacteria requiring long term treatment such as endocarditis, prosthetic joint infections (PJI) or osteomyelitis. Clinical data are limited in these settings. To evaluate indications, safety, tolerability and long-term outcomes of dalbavancin-treated patients. Patients and methods Our multicenter, retrospective study includes patients who received dalbavancin in Austria from September 2016 to March 2018. 90-day outcomes and tolerability were determined. A total of 101 patients were included in 3 centers (57% male, median age 65 years). The treated infections were PJI (31%), osteomyelitis (29%), endocarditis (25%) and acute bacterial skin and soft tissue infections (12%). Concomitant use of other antimicrobial substances was common (63%). The mean total cumulative dose of dalbavancin was 3,357mg (±2,283mg). Clinical success rate was 89%. Side effects occurred in 3/101 patients. In this real-life study dalbavancin was primarily used in off-label indications for treatment of PJI, osteomyelitis and endocarditis. Success rate was high (89%), tolerability and safety were excellent in this setting. Dalbavancin may therefore be used in these off-label indications as alternative treatment approach. Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
- Find related publications in this database (Keywords)
- Dalbavancin
- Osteomyelitis
- PJI
- Endocarditis